Selected article for: "acute respiratory distress syndrome and lymphocyte count neutrophil count"

Author: Quartuccio, Luca; Fabris, Martina; Sonaglia, Arianna; Peghin, Maddalena; Domenis, Rossana; Cifù, Adriana; Curcio, Francesco; Tascini, Carlo
Title: Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia
  • Cord-id: ckv3urpe
  • Document date: 2021_1_15
  • ID: ckv3urpe
    Snippet: Background Patients infected by SARS-CoV-2 can develop interstitial pneumonia, requiring hospitalisation or mechanical ventilation. Increased levels of inflammatory biomarkers are associated with development of acute respiratory distress syndrome (ARDS). The aim of the present study was to determine which cytokines are associated with respiratory insufficiency in patients hospitalised for COVID-19. Patients and methods Data on 67 consecutive patients were collected between March 8 and March 30,
    Document: Background Patients infected by SARS-CoV-2 can develop interstitial pneumonia, requiring hospitalisation or mechanical ventilation. Increased levels of inflammatory biomarkers are associated with development of acute respiratory distress syndrome (ARDS). The aim of the present study was to determine which cytokines are associated with respiratory insufficiency in patients hospitalised for COVID-19. Patients and methods Data on 67 consecutive patients were collected between March 8 and March 30, 2020. PaO2/FiO2 ratio (P/F) was calculated at hospital admission. The following cytokines were analysed: interleukin (IL)-6, IL-1α, IL-18, tumour necrosis factor (TNF)-β, macrophage colony-stimulating factor (M-CSF), macrophage migration inhibitory factor (MIF), soluble IL-2 receptor alpha (sIL-2Rα; CD25), IL-12β, IL-3, interferon (IFN) α2a, monokine induced by gamma interferon (MIG), monocyte-chemotactic protein 3 (MCP3) and hepatocyte growth factor (HGF). Results P/F lower than 300 was recorded in 22 out of 67 patients (32.8%). P/F strongly correlated with IL-6 (r = –0.62, P <0.0001), M-CSF (r = –0.63, P <0.0001), sIL-2Rα (r = –0.54, P <0.0001), and HGF (r = –0.53, P <0.0001). ROC curve analyses for IL-6 (AUC 0.83, 95% CI 0.73–0.93, P <0.0001), M-CSF (AUC 0.87, 95% CI 0.79–0.96, P < 0.0001), HGF (AUC 0.81, 95% CI 0.70–0.93, P < 0.0001), and sIL-2Rα (AUC 0.80, 95% CI, 0.69–0.90, P <0.0001) showed that these four soluble factors were highly significant. All four soluble factors correlated with LDH, white blood cell count, neutrophil count, lymphocyte count, and CRP. Conclusion IL-6, M-CSF, sIL-2Rα, and HGF are possibly involved in the main biological processes of severe COVID-19, mirroring the level of systemic hyperinflammatory state, the level of lung inflammation, and the severity of organ damage.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung inflammation level: 1
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute ards respiratory distress syndrome and lung physiology: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome development and lung inflammation: 1, 2, 3
    • acute ards respiratory distress syndrome development and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute ards respiratory distress syndrome development and lung physiology: 1
    • acute ards respiratory distress syndrome development and lymphocyte count: 1
    • acute lung injury and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury and lung level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute lung injury and lung physiology: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute lung injury and lymphocyte activation: 1
    • acute lung injury and lymphocyte count: 1, 2, 3
    • acute lung injury and lymphopenia mechanism: 1
    • acute lung injury progress and lung inflammation: 1
    • acute lung injury progress and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9